

**To:** [REDACTED] [REDACTED] [REDACTED]@yahoo.com]  
**From:** Lesley Groff  
**Sent:** Thur 1/17/2019 5:18:48 PM  
**Subject:** Re: Catching Up

Hi [REDACTED] ...all is good! I will forward this on for you...  
Hope all is well with you too.

Lesley

On Jan 17, 2019, at 12:09 PM, [REDACTED] [REDACTED]  
<[REDACTED]> wrote:

Hi Lesley,

I hope you're well! It's been a while since I was in touch! I emailed Jeffrey and Rich last night but wasn't sure that they still use the email addresses that I have. Thank you for forwarding this onto to them if you can.

I hope to see you soon! My cell is: [REDACTED] if you ever need to reach me.

all the very best,

[REDACTED]



<1506365439123blob.jpg>

----- Forwarded Message -----

**From:** [REDACTED] [REDACTED] <galbraith [REDACTED]>  
**To:** jeevacation@gmail.com <jeevacation@gmail.com>; [REDACTED]  
[REDACTED]  
**Sent:** Wednesday, January 16, 2019, 11:22:06 PM EST

**Subject:** Catching Up

Dear Jeffrey

I hope you've been well. I wanted to update you on what I've been up to for the last two years. I was also hoping to talk with you to see if I might use the foundation's Lexington office conference room from time to time for my work and what I could provide in exchange for that. I am cc'ing Rich because I'm not sure if you still use this email?

Since working for your foundation, I continued to publish as a journalist writing mostly about genetic vectors (*Newsweek*, *Techonomy* etc). I then set up an LLC that provides business development for labs that have reversed age-driven or degenerative diseases. Most of the therapies are genetic vectors, and have to show remarkable results at the mouse level and beyond. Regenerative medicine is a rapidly evolving field, and one that forces the medical industry to shift their focus from addressing symptoms of disease to fundamental evolutionary shortfalls.


So far, I placed a genetic vector at the National Institute of Medicine in France (that reversed glaucoma in mice using the neuroglobin gene) under formal licence review with a publicly traded pharma group here in the US. And I am collaborating with a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver disease in rats using the master transcription gene in hepatocytes. The concept of the latter gene vector is really intriguing in that a master transcription gene completely restored liver function by rebalancing genetic expression and thus proteostasis.

While I don't really need an office at this point, I do need access to a conference room from time to time and it would be hugely helpful if I could access the foundation's. If there was some work that I could do for the foundation in exchange, I would be delighted to do that.

It would be wonderful to catch up with you as well.

all the best,





<1506365439123blob.jpg>

<1506365439123blob.jpg><1506365439123blob.jpg>